Process for preparing β-artemether

A technology of artemether and methanesulfonic acid, applied in the field of synthesis of β-artemether, can solve the problems such as that the yield of β-artemether cannot be further improved, and achieves easy control of process operation, high product quality and low cost Effect

Active Publication Date: 2015-09-23
SHANGHAI DESANO PHARMA INVESTMENT +2
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] When the present inventors synthesized β-artemether according to the method disclosed in the above-mentioned documents, they found that about 15% of α-artemether would be produced in the reaction process, so the yield of β-artemether could not be further increased.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Process for preparing β-artemether

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0021] The method for preparing β-artemether of the present invention only uses trimethyl orthoformate as the etherifying agent.

[0022] The method for preparing β-artemether of the present invention comprises the following steps: taking dihydroartemisinin as a raw material, and performing etherification reaction with trimethyl orthoformate in an organic solvent to obtain β-artemether.

[0023] The organic solvent is selected from ester solvents or alkane solvents.

[0024] The ester solvent is selected from methyl formate, ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate, dimethyl carbonate, diethyl carbonate, Propyl carbonate or isopropyl carbonate. Methyl acetate or ethyl acetate is preferred.

[0025] The alkane solvent is selected from n-hexane, n-heptane or petroleum ether.

[0026] The catalyst is selected from boron trifluoride ether, trifluoroacetic acid, p-toluenesulfonic acid or methanesulfonic acid...

Embodiment 1

[0032] Under nitrogen protection, dihydroartemisinin (40.0 g, 0.14 mol) was added to 150 ml of ethyl acetate and trimethyl orthoformate (10.5 ml, 0.096 mol); cooled in an ice bath, the temperature of the system was lowered to 0 At °C, a solution of boron trifluoride ether (2.0 ml, 0.016 mol) in ethyl acetate (50 ml) was added dropwise. After the dropwise addition, the reaction was continued at 0°C for 2 hours. The ice bath was removed, the temperature was naturally raised to room temperature, and the reaction was continued for 1 hour. The reaction was followed by TLC. After confirming that the reaction was complete, the temperature was cooled to 5° C., and a saturated sodium bicarbonate solution was added dropwise to adjust the pH to 7-8. The layers were separated, the organic layer was washed once with saturated brine, dried over anhydrous magnesium sulfate, and distilled under reduced pressure to obtain about 43 g of semi-solid.

[0033] 43 g of the obtained crude product ...

Embodiment 2

[0035] Dihydroartemisinin (40 g, 0.14 mol) was added to 150 ml of methyl acetate and trimethyl orthoformate (12.0 ml, 0.11 mol); cooled in an ice bath, the temperature of the system was lowered to 5 °C, and methanesulfonic acid was added dropwise Acid (1.0 mL, 7.9 mmol) in methyl acetate (50 mL). After the dropwise addition was completed, the reaction was continued at 5°C for 1 hour. The ice bath was removed, the temperature was naturally raised to room temperature, and the reaction was continued for 1 hour.

[0036] The post-processing method was the same as that in Example 1, and 38.2 g of β-artemether was obtained, with a molar yield of 91.5%, a purity of 99.5% detected by HPLC, and a single impurity of less than 0.1%. NMR data as above.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Provided is a method for synthesizing beta-Artemether. The method uses dihydroartemisinin as a raw material, which has an etherifying reaction with trimethyl orthoformate in an organic solvent in the presence of catalyst, to give beta-Artemether, with a byproduct alpha-Artemether content of less than 6%.

Description

technical field [0001] The invention belongs to the technical field of medicinal chemistry, in particular to a method for synthesizing beta-artemether. Background technique [0002] Malaria is the mosquito-borne infectious disease with the highest incidence and the most serious harm in the world, especially P. falciparum, which still threatens the health of hundreds of millions of residents in tropical and subtropical countries. Artemether is a derivative of artemisinin. It is a special drug independently developed by China to treat various critical malaria patients and rescue cerebral malaria patients. It has the advantages of high efficiency, low toxicity, convenient use, and no cross-resistance with chloroquine. , is the preferred antimalarial drug recommended by the World Health Organization (WHO), and has been included in the core list of essential medicines by WHO. [0003] Artemether has two epimers, α-artemether and β-artemether. The main one with antimalarial activ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D493/18A61P33/06
CPCC07D493/18A61P33/06
Inventor 李金亮赵楠姜飞郑玉青姚晓光
Owner SHANGHAI DESANO PHARMA INVESTMENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap